Loading...
Mobileye Global Inc (MBLY) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces near-term headwinds, including insider selling, bearish technical indicators, and mixed analyst sentiment. While the company has long-term potential in autonomous driving and robotics, the current financial performance and guidance suggest significant challenges in the short to medium term. A hold is recommended until clearer signs of recovery or growth emerge.
The technical indicators show a bearish trend. The MACD is above 0 but contracting, indicating weakening momentum. RSI is neutral at 34.933, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 8.635, with resistance at 9.533. Overall, the technical outlook suggests caution.

The integration of EB corbos Linux for Safety Applications into Mobileye Drive is a significant advancement in autonomous driving technology, enhancing safety and functionality. This partnership supports global OEMs and robotaxi vendors, aligning with long-term growth prospects.
Insiders are selling heavily, with a 94071.64% increase in selling activity over the last month. Financial performance in Q4 2025 showed an 8.98% YoY revenue decline and a gross margin drop of 7.91%. Analysts have lowered price targets and expressed concerns about near-term headwinds, including elevated R&D expenses and OEM insourcing. The stock has a 60% chance of declining 7.07% in the next month.
In Q4 2025, revenue dropped to $446M (-8.98% YoY), while net income improved to -$127M (+78.87% YoY). EPS increased to -0.16 (+77.78% YoY), but gross margin declined to 45.29% (-7.91% YoY). The financials indicate cost pressures and limited growth, with guidance for FY26 revenue growth below expectations.
Analyst sentiment is mixed. Tigress Financial maintains a Buy rating with a $25 price target, citing long-term opportunities in ADAS, robotaxis, and robotics. However, several firms, including UBS, HSBC, and Morgan Stanley, have downgraded the stock or lowered price targets, citing near-term challenges such as elevated operating expenses and OEM insourcing. Price targets range from $11 to $25, reflecting uncertainty.